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ent comparison/substitute: the RA for the
vein graft. Dr Lytle’s comment in his
editorial, “in my judgment, the RA graft
is less predictable than the RITA graft in
regard to patency,” intrigued me. Over
the past 15 years as a practicing cardio-
thoracic surgeon, I have become pro-
foundly aware of the inadequacy of
veins, and since my recent attendance at
the enlightening and energy-invoking
symposium “Arterial Conduits for Myo-
cardial Revascularization” in Rome by
Dr G. F. Possatti and Dr A. M. Calafiore,
I believe the thrust should be to continue
to use double ITA grafts whenever pos-
sible (especially in the young) but to sub-
stitute the RA for the vein graft. Since
my return from this symposium, I have
tried to do this; perhaps I did not see (or
did not want to see) before, but many
patients have serious venous disease of
their legs precluding use of the saphe-
nous vein. I think one of the turning
points for me was when I recently (July
24, 2003) had to reoperate on an 83-year-
old woman, on whom I had placed 2
grafts at age 81. Her LITA had gone
down, I believe because I placed the graft
inadvertently above a stenosis and her
vein graft to a marginal artery occluded.
If her vein graft had stayed open, she
probably would not have needed reopera-
tion at age 83. I used a sequential RA
graft to the left anterior descending cor-
onary artery and the marginal branch on-
pump, and postoperatively she woke up
stating that this was easier than her first
operation. (Obviously this time both
grafts were working!)
A second reason to substitute the vein
for the RA graft could be the anticipated
longer-lasting results of the drug-eluting
stents used by interventional cardiolo-
gists. I know we are all interested in the
same end—stamping out coronary artery
disease effects— but it can be a little dis-
concerting for many surgeons currently
in practice to see their favored coronary
artery bypass grafts (LITA plus 2 veins)
going the way of the dodo bird. I want to
be so bold as to predict that the drug-
eluting stents will rival our saphenous
vein grafts (that is, by the time they fig-
ure out which drug, from which drug
family, how much eluting, over what pe-
riod of time, and so on, works; it might
take 20 years). Although we should never
be competitive with our interventional
colleagues because we have the same end
point in common, we must as surgeons
find something ancillary to their work. I
believe total arterial grafting (be it bilat-
eral ITA, LITA/RA, RITA, bilateral ITA/
gastroepiploic artery) may well be the
answer. As Dr Lytle most wisely stated at
the 2003 meeting of The American As-
sociation for Thoracic Surgery in Boston
(and I quote him often in this): “Did you
think you were going to be doing the
same operation for 100 years!?” Dr Lytle
continues to be a driving force leading all
our quests for the best coronary artery
bypass conduit.
Teresa Kieser, MD, FRCSC, FACS
Department of Cardiac Sciences
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inhibitors predispose to hypotension
refractory to norepinephrine but
responsive to methylene blue
To the Editor:
We read with interest the brief communi-
cation of Grayling and Deakin1 describing
the methylene blue administration in a pa-
tient with refractory hypotension during
cardiac surgery. We’re currently using this
drug for patients with high cardiac output
and hypotension unresponsive to norepi-
nephrine at doses similar to those sug-
gested by Grayling and Deakin (up to 3
mg/kg in 2 different administration instead
of 2 mg/kg in a single dose). We would like
to suggest a possible predisposing factor of
vasoplegia that responds to methylene
blue: in our experience2 and in the litera-
ture3-5 it is evident that most episodes of
refractory hypotension are related to pre-
operative intake of angiotensin-converting
enzyme inhibitors (ACEI); even the patient
described in this report was assuming
ACEI (ramipril). After experiencing a dra-
matic refractory hypotension in a patient on
a program of ACEI,2 we started using
methylene blue in case of refractory hypo-
tension and withdrawing ACEI the day be-
fore surgery. We observed an immediate
and sustained response even at doses less
than 1 mg/kg.
We would like to reinforce this kind of
therapeutic approach and suggest a com-
mon predisposing factor that has been so
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Modified Fontan procedure in adults
To the Editor:
At the outset I must congratulate and thank
the authors of this article for this landmark
work on the Fontan procedure in an adult
population.1 This is going to be a bench-
mark for adult Fontan procedure in years to
come.
In the Western hemisphere the Fontan
surgery is done in children; adult patients
undergoing this procedure are exceptions,
not the rule. But in developing countries
adult patients for univentricular palliation,
with or without prior surgical palliation,
are quite common.2 As the authors have
addressed, the primary issue for these pa-
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tients is suitability for surgery. I am unclear
on a few points in the article, however, and
have some questions for the authors.
This landmark work began just after
introduction of the Fontan principle. Is this
why initial modifications were done in a
majority of patients? Or is there another
reason? Do you continue to do these mod-
ifications today? If so, for what indications
and why? The issue of superiority of 1
modification over others in long-term re-
sults is far from resolved. For budding car-
diac surgeons like me, which type of mod-
ification do you recommend for
hemodynamically adequate adult patients?
In other words, what should govern my
choice of modification in different sets of
patients?
The fenestrated Fontan modification has
widened the horizon of univentricular re-
pair. You have elaborately described your
point. Do you feel in spite of anticoagula-
tion the incidence of thromboembolic and
other side effects or complications out-
weighs the benefit of fenestration in de-
creasing the morbidity of procedure, which
has been vigorously tested? Does the age of
the patients also affect the decision to fe-
nestrate? If yes, in what way?2,3
What is your policy regarding 1-stage
or 2-stage procedure? For example, do you
perform superior cavopulmonary first and
then complete the Fontan as a separate pro-
cedure, especially for patients without pal-
liation or with systemic to pulmonary ar-
tery shunts or pulmonary artery banding? Is
the principle of gradual volume unloading
of the ventricle different in adults than chil-
dren?
Once again, I thank the authors for this
outstanding article.
Manoj Purohit
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Reply to the Editor:
In the setting of single ventricle physiol-
ogy, the common and accepted practice is
to proceed with the Fontan procedure at 2
to 4 years of age in the majority of circum-
stances. In developing countries, the oppor-
tunity for staged palliation with eventual
Fontan procedure in young children is less
common. Some children may have under-
gone a palliative operation with a systemic-
to-pulmonary artery shunt or cavopulmo-
nary shunt during early childhood but were
lost to follow-up or never had the opportu-
nity for the completion Fontan procedure.
Consequently, there are potentially a
greater number of older patients who may
be candidates for the Fontan procedure in
developing countries.
In our experience with more than 1000
patients, surgical modifications to the Fon-
tan procedure have evolved over the last 3
decades in an effort to avoid complications
occurring late after operation. Currently,
the technique of the Fontan procedure that
is applied in our patients includes the total
cavopulmonary connection with an extra-
cardiac conduit or intra-atrial conduit. We
believe this technique will minimize the
incidence of late atrial arrhythmias.
To reduce the risk of thromboembo-
lism, we eliminate blind stumps (eg, seg-
ment above the pulmonary valve) and blind
intracardiac chambers (eg, vestigial right
ventricle in tricuspid atresia via the ventric-
ular septal defect) that are exposed to the
systemic circulation. This is accomplished
by patch or suture closure of the pulmonary
valve annulus or closure of the ventricular
septal defect.
When significant risk factors for early
mortality are present prior to the Fontan
procedure, such as severe atrioventricular
valve regurgitation, severe pulmonary ar-
tery abnormalities, or severe subaortic ste-
nosis, we would proceed with a staged sur-
gical approach that corrects these
abnormalities prior to the completion Fon-
tan procedure. This would include repair or
replacement of the atrioventricular valve,
relief of pulmonary artery stenosis or dis-
tortion, and relief of subaortic stenosis (re-
section or Damus-Stansel-Kaye anastomo-
sis). A concomitant bidirectional
cavopulmonary anastomosis is also com-
monly performed at this time. The comple-
tion of the Fontan procedure would then be
performed at a subsequent operation. Mi-
nor intracardiac or pulmonary artery abnor-
malities are corrected at the time of the
Fontan procedure. In the absence of risk
factors, we do not believe it is necessary to
perform a bidirectional cavopulmonary
shunt prior to the Fontan procedure.
We have used the fenestration selec-
tively at the time of the Fontan procedure.
Although we attempt to correct major ab-
normalities during the course of a staged
surgical approach in an effort to reduce
operative risk, some reversible risk factors
for early or late mortality may still be
present. These may include elevated preop-
erative pulmonary artery pressure, revers-
ible ventricular dysfunction, increased ven-
tricular mass, or uncorrected pulmonary
artery abnormalities. Fenestration has also
been used in patients with predominant
right ventricular morphology.
The role of warfarin anticoagulation af-
ter the Fontan procedure has been contro-
versial. In general, we tend to anticoagulate
most adult patients, particularly those with
a fenestration or residual intracardiac
shunt, history of arrhythmias, intracardiac
thrombus, slow circulation, and venous
varices. In children and young adult pa-
tients, we may substitute aspirin as an al-
ternative to warfarin anticoagulation.
Joseph A. Dearani, MD
Francisco J. Puga, MD
Gordon K. Danielson, MD
Division of Cardiovascular Surgery,
Mayo Clinic, Rochester, MN 55905
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Mitral valve surgery with extensive
calcification of the annulus
To the Editor:
Feindel and coauthors1 report results in a
challenging set of patients, those with mi-
tral annular calcification (MAC) causing
mitral regurgitation. Several alternative
techniques to avoid excising the calcified
bar all have disadvantages. Displacing the
prosthetic sewing line into the left atrium
(with or without a prosthetic cuff) subjects
the left atrium to high ventricular pressure.
Sewing to the mitral leaflets central to the
calcified bar requires sewing to fragile tis-
sue and downsizing the valve. Sewing to
the calcified bar usually leads to dehis-
cence, and trying to pass the sutures around
the bar jeopardizes the circumflex coronary
artery.
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